Previous 10 | Next 10 |
Image source: The Motley Fool. ADC Therapeutics SA (NYSE: ADCT) Q2 2021 Earnings Call Aug 03, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: ADC Therapeutics SA (ADCT) Q2 2021 Earnings Call Transcript
The following slide deck was published by ADC Therapeutics SA in conjunction with their 2021 Q2 earnings call. For further details see: ADC Therapeutics SA 2021 Q2 - Results - Earnings Call Presentation
- Encouraging initial launch of ZYNLONTA™ (loncastuximab tesirine-lpyl) driven by favorable product profile to address high unmet medical need in relapsed / refractory DLBCL market - Company to host conference call today at 8:30 a.m. EDT ADC Therapeutics SA (N...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Tuesday, Augu...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
ADC Therapeutics ([[ADCT]] -1.0%) has announced updated interim results from the ongoing pivotal Phase 2 clinical trial of antibody-drug conjugate, camidanlumab tesirine (Cami) in patients with relapsed or refractory Hodgkin lymphoma.The open-label, single-arm study involving 117 su...
Phase 2 dosing schedule results in encouraging overall response rate and long-lasting treatment effects in heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma Phase 2 safety profile, including incidence of GBS, consistent with Phase 1 ADC Therap...
Dr_Microbe/iStock via Getty Images Today's up to $3B development and commercialization deal from Bristol-Myers Squibb (BMY) for Eisai's (ESALY) for MORAb-202 is putting antibody drug conjugates ("ADCs"), which some feel is the future of cancer therapeutics, into the spotlight. The o...
ADC Therapeutics (ADCT) announces that posters on four Zynlonta (loncastuximab tesirine-lpyl) clinical trials were presented at the 16th Annual International Conference on Malignant Lymphoma ((ICML)). In Phase 2 LOTIS-2 trial in patients with relapsed or refractory diffuse large B-cell lympho...
LOTIS-2 updated results demonstrate durable responses of ZYNLONTA ™ with median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCL LOTIS-3 updated Phase 1 data highlight potential of ZYNLONTA™ in combinat...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...